Vanda Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:VNDA)

view original post

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) saw unusually large options trading on Friday. Stock investors acquired 4,024 call options on the stock. This is an increase of approximately 1,070% compared to the average daily volume of 344 call options.

In other news, CEO Mihael Hristos Polymeropoulos sold 46,200 shares of the company’s stock in a transaction dated Wednesday, December 1st. The stock was sold at an average price of $16.00, for a total value of $739,200.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 6.10% of the stock is owned by corporate insiders.

Several hedge funds have recently modified their holdings of VNDA. Meeder Asset Management Inc. boosted its stake in shares of Vanda Pharmaceuticals by 3,824.8% during the 3rd quarter. Meeder Asset Management Inc. now owns 4,435 shares of the biopharmaceutical company’s stock worth $77,000 after acquiring an additional 4,322 shares in the last quarter. FORA Capital LLC bought a new stake in shares of Vanda Pharmaceuticals during the 2nd quarter worth $129,000. Schonfeld Strategic Advisors LLC bought a new stake in shares of Vanda Pharmaceuticals during the 3rd quarter worth $172,000. Grantham Mayo Van Otterloo & Co. LLC bought a new stake in shares of Vanda Pharmaceuticals during the 3rd quarter worth $225,000. Finally, Profund Advisors LLC bought a new stake in shares of Vanda Pharmaceuticals during the 2nd quarter worth $231,000. Institutional investors own 98.42% of the company’s stock.

Shares of Vanda Pharmaceuticals stock opened at $15.38 on Friday. The business’s 50 day simple moving average is $17.07 and its 200-day simple moving average is $17.57. The stock has a market capitalization of $856.85 million, a price-to-earnings ratio of 25.21 and a beta of 0.44. Vanda Pharmaceuticals has a twelve month low of $13.36 and a twelve month high of $21.86.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its earnings results on Wednesday, November 3rd. The biopharmaceutical company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.20 by ($0.06). Vanda Pharmaceuticals had a net margin of 12.77% and a return on equity of 7.23%. The business had revenue of $70.10 million during the quarter, compared to analyst estimates of $73.50 million. During the same quarter in the prior year, the business earned $0.11 earnings per share. As a group, research analysts forecast that Vanda Pharmaceuticals will post 0.55 EPS for the current year.

Separately, Zacks Investment Research downgraded Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Friday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, Vanda Pharmaceuticals has an average rating of “Hold” and an average target price of $18.50.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals, Inc engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051.

Featured Story: How do candlesticks reflect price movement?

Want More Great Investing Ideas?